IN8bio, Inc.
IN8bio, Inc. (INAB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · INAB · as of Sep 30, 2025
Ownership Breakdown
20
Institutional Holders
▲ 8 vs Q2
$2.13M
Total Inst. Value
▲ $297,562 vs Q2
4.64M
Shares Outstanding
freeFloat 71.13%
980,421
13F Shares Held
▲ 104,940 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
INAB largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BIOS CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 286.7K | 6.32% | 6.32% | $622.06M | Nov 12, 2025 | — held |
FRANKLIN RESOURCES INC biological products, (no diagnostic substances) | 189.9K | 4.18% | 4.18% | $412.07M | Nov 13, 2025 | — held |
STONEPINE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 159.4K | 3.51% | 3.51% | $345.94M | Nov 13, 2025 | ▲ 77.0K |
ALYESKA INVESTMENT GROUP, L.P. biological products, (no diagnostic substances) | 82.5K | 1.82% | 1.82% | $178.99M | Nov 17, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 59.4K | 1.31% | 1.31% | $128.94M | Nov 7, 2025 | ▼ 679 |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 49.5K | 1.09% | 1.09% | $107.31M | Nov 14, 2025 | NEW |
TWO SIGMA ADVISERS, LP biological products, (no diagnostic substances) | 45.8K | 1.01% | 1.01% | $99.28M | Nov 14, 2025 | NEW |
JANE STREET GROUP, LLC biological products, (no diagnostic substances) | 26.2K | 57.70% | 57.70% | $56.81M | Nov 14, 2025 | NEW |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 24.7K | 54.49% | 54.49% | $53.66M | Nov 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 19.3K | 42.52% | 42.52% | $41.87M | Nov 12, 2025 | ▲ 472 |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
4
Increased
+79.0K shares9
New Positions
first time holders3
Decreased
−1.3K shares1
Sold Out
fully exitedNet shares change (top 50)
+77.7K
+79.0K / −1.3K
Net new holders
+9
9 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
INAB insider trading · insider activity
Source: SEC Form 4
9
Buy transactions
1
Sell transactions
9.00
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
FAIRBAIRN EMILY director | May 27, 2026 | Gift | 724,637 | — | — | 0 | Form 4 ↗ |
Ho William Tai-Wei CEO | May 9, 2026 | Award | 154,500 | $1.58 | $244.1K | 154.5K | Form 4 ↗ |
Greenwood Luba director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
Lamb Lawrence EVP and CSO | May 9, 2026 | Award | 54,000 | $1.58 | $85.3K | 54.0K | Form 4 ↗ |
FAIRBAIRN EMILY director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
McCall Patrick CHIEF FINANCIAL OFFICER | May 9, 2026 | Award | 56,250 | $1.58 | $88.9K | 56.3K | Form 4 ↗ |
Rochlin Kate President and COO | May 9, 2026 | Award | 60,000 | $1.58 | $94.8K | 60.0K | Form 4 ↗ |
Epperly Corinne director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
Brandt Peter C. director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
Graff Jeremy R. director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
IN8bio, Inc. (INAB) is primarily owned by institutional investors, who hold approximately 21.1% of total shares outstanding. Company insiders own approximately 28.87%, while retail and public investors account for the remaining 49.98%.
The largest institutional shareholder of IN8bio, Inc. is BIOS CAPITAL MANAGEMENT, LP, holding approximately 286,664 shares — equal to 6.32% of outstanding shares — as of September 30, 2025.
A total of 20 institutional investors currently hold INAB stock, with a combined institutional value of approximately $2,127,322 as of the most recent 13F filing period.
Frequently asked questions
INAB ownershipIN8bio, Inc. (INAB) is primarily owned by institutional investors, who hold approximately 21.1% of shares. The largest shareholder is BIOS CAPITAL MANAGEMENT, LP with a 6.32% stake. Company insiders hold 28.87%. Data sourced from SEC Form 13F as of September 30, 2025.